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Abstract
Introduction:
Currently there are approximately 1.2 million people in the United States living with HIV
and it is estimated that 25.6% of HIV-positive adults suffer from depression. The purpose
of this study is to examine the contribution of depression on substance use and
medication adherence specifically among HIV-positive adult Georgians receiving
medical care for HIV.
Methods:
Secondary data with a probability sample of 608 HIV-positive adults who took part in the
2009-2012 Georgia Medical Monitoring Project (MMP) were analyzed. Descriptive
analysis and multivariate logistic regression models were conducted to assess
relationships between depression with current cigarette smoking, injection drug use, other
non-injection drug use, and medication adherence, adjusting for sociodemographic
covariates (age, gender, race, and education). All analyses accounted for non-response
and complex sampling design and were performed using SAS 9.2 (Cary, NC).
Results:
Among HIV-positive adults in Georgia, approximately 9.2% met the criteria for major
depression; 15.2% of women and 6.9% of men had major depression. Heterosexual adults
also had a higher percentage of major depression (11.9%) compared to adults who
identified as bisexual (8.3%) or homosexual (6.1%). Major depression was also highest
among young adults (17.1%) and adults with high school diploma or GED (13.0%).
Major depression was associated with a greater odds of current cigarette smoking (3.04;
95% CI: 1.48, 6.23); injection drug use (5.62; 95% CI: 0.96, 32.81), and other noninjection drug use (2.17; 95% CI: 1.10, 4.25), after adjusting for sociodemographic
variables. Major depression was also associated with a greater odds of ART medication
non-adherence, 2.52 (95% CI: 1.20, 5.28), after adjusting for gender.
Conclusion:
As previously found in the general population, we found significant associations between
depression and smoking and other non-injection drug use among HIV-positive adults.
Major depression was also associated with a greater odds of ART medication nonadherence, which is also consistent with the literature. Because HIV-positive adults have
ongoing encounters with healthcare providers, screening and treatment for depression and
other co-morbid substance use is needed to reduce an additional health burden in this
population.
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CHAPTER I: Introduction
1.1 Background
Approximately 1.2 million people within the United States are currently living
with Human Immunodeficiency Virus (HIV), and nearly 14% are not aware of their HIV
infection (“CDC - HIV/AIDS”). The CDC estimates 50,000 new HIV infections each
year (“CDC - HIV/AIDS”). According to the Georgia Department of Public Health
HIV/AIDS Epidemiology Section, approximately 50, 436 people were living with HIV in
Georgia as of December 31, 2012 (The Georgia Department of Public Health Fact Sheet:
HIV Surveillance, Georgia, 2012). Georgia has the sixth highest HIV prevalence among
adults and adolescents in the United States, and Georgia ranked fourth highest in the
United States for new HIV infections in 2011 (The Georgia Department of Public Health
Fact Sheet: HIV Surveillance, Georgia, 2012).
If left untreated, HIV leads to acquired immunodeficiency syndrome (AIDS). HIV
impairs the immune system by destroying CD4 cells. HIV is classified into three stages
which are measured by CD4 counts. Stage three is when CD4 levels are the lowest,
classified as AIDS. Although there is no cure at this time, treatment with antiretroviral
therapy (ART) is highly effective at improving the quality and longevity of life among
people living with HIV. ART lowers a person’s viral load and decreases the risk of
transmission (The Georgia Department of Public Health Fact Sheet: HIV Surveillance,
Georgia, 2012).
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Adults with HIV experience multiple comorbid social, behavioral, physical, and
mental health problems. For example, adults with HIV may deal with stigma and
discrimination, and this may lead to chronic stress and substance use. Adults with HIV
also may engage in more risk taking behaviors such as unprotected sex or needle-sharing
injection drug use, and because many persons may not know they are infected, risk taking
behaviors by persons with HIV may further increase the likelihood of spreading the virus.
While individuals living with HIV are living longer lives compared to the era
before ART, complications and barriers still exist linking and retaining individuals with
HIV to treatment and care. Specific comorbidities are common to people living with
HIV. Mental illness, specifically depression, disproportionately affects this population.
The presence of depression among HIV-positive adults is strongly suspected to be a
barrier to accessing and remaining in care.
1.2 Purpose of the study
The purpose of this study is to examine the association of major depression with
current cigarette smoking, injection drug use, other non-injection drug use, and
medication adherence, among adults in Georgia receiving medical care for HIV infection
using the Georgia Medical Monitoring Project Data, 2009-2012.
1.3 Hypotheses
The four null hypotheses will be tested using multivariate logistic regression: (1) Among
adults residing in Georgia living with HIV, major depression will have no association
with current cigarette smoking, (2) Among adults residing in Georgia living with HIV,
major depression will have no association with injection drug use, (3) Among adults
residing in Georgia living with HIV, major depression will have no association with other
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non-injection drug use, and (4) Among adults residing in Georgia living with HIV, major
depression will have no association with ART medication adherence.

CHAPTER II: Literature Review
2.1 Epidemiology of HIV
Approximately 1.2 million people within the United States are currently living
with Human Immunodeficiency Virus (HIV) (“CDC - HIV/AIDS”). Currently, African
Americans are most affected by HIV in the United States. African American’s rate of
infection is nearly 8 times compared to whites (“CDC - HIV/AIDS”). African Americans
also have a higher proportion of new HIV infections, a higher prevalence of HIV
infections, and a higher proportion of persons ever diagnosed with AIDS (“CDC HIV/AIDS”). An estimated 44% of all new HIV infections among individuals 13 or older
were African Americans, and among those, an estimated 70% were men. More new HIV
infections were among African American men who have sex with men, ages 13 to 24,
than other men who have sex with men (“CDC - HIV/AIDS”).
In the United States, 75% of all adults living with HIV were men, and the
majority of those individuals were men who have sex with men (“CDC - HIV/AIDS”).
Among women, most new HIV infections are from heterosexual contact (“CDC HIV/AIDS”). As with men, African American women are disproportionately affected by
HIV compared to other races; nearly 64% of HIV-positive women are African American.
Also, women overall are not receiving adequate care for their HIV in the United States.
Only 45% of HIV-positive women were retained in care (“CDC - HIV/AIDS”).
Similar trends are observed in Georgia compared to national HIV epidemiology.
According to the Georgia Department of Public Health HIV/AIDS Epidemiology
Section, approximately 50, 436 people were living with HIV in Georgia as of December
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31, 2012 (The Georgia Department of Public Health Fact Sheet: HIV Surveillance,
Georgia, 2012). Georgia has the sixth highest HIV prevalence among adults and
adolescents in the United States, and Georgia ranked fourth highest in the United States
for new HIV infections in 2011 (The Georgia Department of Public Health Fact Sheet:
HIV Surveillance, Georgia, 2012). Men account for 78% of new HIV infections, and
55% of all new HIV infections were African American.
2.2 Epidemiology of Depression among Adults in the U.S. Population
During 2009-2011, an annual average of 19.9% of adults had a mental illness,
including individuals with depression, schizophrenia, and bipolar disorders (Centers for
Disease Control and Prevention (CDC), 2013). Among these individuals, the highest
proportion of mental illness was among adults ages 18 to 24 and among women. An
estimated 23.4% (95% CI, 22.9-23.9) of women had a mental illness compared with
16.1% (95% CI, 15.7-16.6) of men (Centers for Disease Control and Prevention (CDC),
2013). The median state percentage of adults with any mental illness was 20.4%, and
Georgia had a 17.2% percentage of adults with a mental illness (Centers for Disease
Control and Prevention (CDC), 2013). A recent examination of NHANES 2009-2010
revealed that the prevalence of depressive symptoms among adults ages 18 and older was
25.7% (Wittayanukorn, Qian, & Hansen, 2014). Among the 25.7% experiencing
depressive symptoms, 36.6% were classified as having moderate to severe depression
(Wittayanukorn et al., 2014). Furthermore, among those classified as having moderate to
severe depression, only 38.7% were receiving antidepressant medication or seeing a
mental health professional (Wittayanukorn et al., 2014).
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Major depressive disorder, as defined by the Diagnostic and Statistical Manual of
Mental Disorders, fourth edition (DSM-IV), includes experiencing five or more
depressive symptoms (American Psychiatric Association, 2000). These symptoms can
include feeling sad or empty, diminished interest in activities, significant weight loss,
insomnia or hypersomnia, psychomotor agitation, fatigue, feelings of worthlessness, and
an inability to concentrate (American Psychiatric Association, 2013).
There are multiple scales and instruments currently used to assess depression
among the adult population. The Patient Health Questionnaire (PHQ-9) is one such
instrument, which has become an increasingly popular tool in surveillance systems to
assess the 9 criteria for depression as defined by the DSM-IV (American Psychiatric
Association, 2000; K. Kroenke, Spitzer, & Williams, 2001). Recently, a PHQ-8 became
available that consisted of an 8-item version of the PHQ-9 (Kurt Kroenke et al., 2009).
PHQ-8 has demonstrated strong validity and reliability as a measure to assess current
depression (Kurt Kroenke et al., 2009).
2.3 Depression among Adults living with HIV
Among HIV-infected individuals, depression is the most common
neuropsychiatric disorder that affects these individuals (Nanni, Caruso, Mitchell,
Meggiolaro, & Grassi, 2015). The prevalence of depression among HIV-infected
individuals is anywhere between 18 and 81 percent (Arseniou, Arvaniti, & Samakouri,
2014). Depression also disproportionately affects HIV-positive individuals compared to
HIV-negative individuals (Bing et al., 2001). Using the National Medical Monitoring
Project (MMP) and the Behavioral Risk Factor Surveillance System (BRFSS), the
prevalence of any depression among HIV-positive adults in care was 25.6% (95% CI:
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23.8%-27.4%) compared to 9.1% (95% CI: 8.9%-9.4%) of adults in the general
population who had any depression (Do et al., 2014). An estimated 12.4% (95% CI:
11.2%, 13.7%) of HIV-positive adults had major depression compared to 4.1% (95% CI:
3.9%, 4.2%) who had major depression in the general population (Do et al., 2014). This
estimate of 25.6% of HIV-positive adults with any depression is also higher than the
estimated 19.9% of adults in the general population who had a mental illness (Centers for
Disease Control and Prevention (CDC), 2013). Compared to the general population, HIV
positive persons are between two and seven times more likely to be diagnosed with major
depression (Hinkin, Castellon, Atkinson, & Goodkin, 2001; Do et al., 2014). Depression
among people living with HIV is known to have an effect on several health outcomes and
health behaviors (Arseniou et al., 2014).
The relationship between depression and HIV infection is complicated, and the
directionality of causation is often unclear. Depression does not only frequently occur
after HIV diagnosis, but depression can be a risk factor for HIV transmission (Nanni et
al., 2015). Adults with severe mental illness (SMI), including those with depression, are
more likely to engage in risky sexual behavior or use injection drugs, therefore increasing
HIV transmission risk (Meade & Sikkema, 2005). In the study by Do et al., adults who
engaged in one or more HIV risk behaviors had a depression prevalence twice the
depression prevalence of adults who did not engage in HIV risk behaviors (2014).
Biological Etiologies of Depression among persons living with HIV
Depression also frequently occurs after HIV diagnosis. Depression within the
HIV-positive population has several etiologies, including biological and psychosocial
factors (Arseniou et al., 2014). HIV infection may play a role in secondary depression by
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altering biological elements within the brain, leading to depression. One indication that
the HIV virus has infected the central nervous system is the presence of neurocognitive
defects, which also may potentially cause depression (Gibbie et al., 2006). HIV infection
has been linked to alterations of neural networks and white matter structure, alterations of
brain morphology, somatostatin dysregulation, and tryptophan degradation (Gibbie et al.,
2006). Several studies have examined brain structure alterations among HIV-negative
individuals with major depression, and they have found several brain structures actually
morph over time (Milak et al., 2005; Sheline, 2000). These certain brain structures,
including basal ganglia, orbitofrontal cortex, and neural networks, are also vulnerable to
HIV infection, which may cause secondary depression (Arseniou et al., 2014). Long-term
studies are needed to further examine this relationship, but there is evidence linking HIV
infection and depression within the brain structures.
Another biological mechanism that has been hypothesized as linking HIV
infection to depression is hypothalamus-pituitary-thyroid (HPT) dysfunction (Arseniou et
al., 2014). HPT dysfunction, among the HIV-negative population, is known to cause
depression, along with mood disorders and dementia. HIV infection of the CNS may alter
hypothalamus and thyroid communication; therefore, HIV infection of the CNS may
cause depression through this mechanism (Langford, Baron, Joy, Del Valle, & Shack,
2011).
Psychosocial Etiologies of Depression among persons living with HIV
Apart from the biological factors explaining depression diagnoses post-HIV
infection, psychosocial factors among HIV-positive adults also contribute to the
depression etiology in this population. Among the general population, people who are
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newly diagnosed with a chronic illness or disease exhibit elevated levels of depression
(DeJean, Giacomini, Vanstone, & Brundisini, 2013). Among HIV positive individuals,
changes in social support structure and body image, perceived stigma, and occupational
disability contribute to an increase risk of depression (Olatunji, Mimiaga, O’Cleirigh, &
Safren, 2006). Among a study assessing the emotions of newly diagnosed men and
women in the San Francisco area, a qualitative analysis revealed several common themes
about initial diagnosis, including concerns about dying, stigma, and a threat to identity
(Moskowitz, Wrubel, Hult, Maurer, & Acree, 2013).
Depression’s Impact on the Progression of HIV
Depression is not only harmful to individuals living with HIV and their sense of
well-being, but one study revealed depressive symptoms were associated with a quicker
development of an AIDS condition compared to individuals without depressive
symptoms (J. Leserman et al., 2002). This rapid progression can be due to a variety of
factors, including individuals with depressive symptoms adhering less to HIV medication
regimen than individuals without depressive symptoms (Soller et al., 2011). Chronic
depression, as well as stressful events and trauma, may negatively influence disease
progression by decreasing CD4 T lymphocytes and increasing risk for mortality
(Leserman, 2003; Leserman, 2008). The extent of this relationship of depression to
biomarkers still needs to be explored; depression may influence psychosocial and
behavioral risk factors, which subsequently influence an increase in viral load or decrease
in CD4 T lymphocytes (Schuster, Bornovalova, & Hunt, 2012).
Early studies revealed depression has a substantial influence on the immune
system. In addition to the influences of depression on the progression of HIV disease, this
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is further worsened by depression’s negative influence on the production of cytotoxic
lymphocytes (Herbert & Cohen, 1993). Hyperactivity of the HPA axis, which results
from major depression, increases glucocorticoid circulation (Pariante & Lightman, 2008).
Glucocorticoids have an effect on the production of interleukins and interferons, which
have a direct impact on lymphocytes’ mechanism of fighting infectious agents (Schuster
et al., 2012).
In addition to these studies, other researchers sought to evaluate depression’s
effect on the immune system in patients on antiretroviral therapy. A small study in Italy
revealed a significant difference in the number of natural killer cells between depressed
individuals and non-depressed individuals (Alciati, Gallo, Monforte, Brambilla, &
Mellado, 2007). These participants were all receiving antiretroviral therapy.
2.4 Depression and Cigarette Smoking among Adults living with HIV
The association between depression and cigarette smoking among the general population
Among the general United States adult population, a strong relationship between
mental illness and tobacco use exists in the general U.S. adult population and also across
US states (Dube et al., 2009; McClave et al., 2009). During 2009-2011, a yearly average
of 19.9% of adults ages 18 and older were living with a mental illness, and among these
adults, 36.1% were current smokers (Centers for Disease Control and Prevention (CDC),
2013). Among the general adult population ages 18 and older, 21.4% of adults are current
smokers, substantially lower than the smoking prevalence among those living with a
mental illness (Centers for Disease Control and Prevention (CDC), 2013). Among
Georgians, an estimated 24% (95% CI, 18.8-30.1) of adults with a mental illness smoke.
Potential reasons for the association between mental illness and tobacco use is the
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psychoactive properties of nicotine, which may help to ameliorate negative affective
states that are symptoms of many types of mental illnesses, including major depression
(McClave, McKnight-Eily, Davis, & Dube, 2010; Strine et al., 2012; Trosclair & Dube,
2010).
Depression and cigarette smoking among persons living with HIV
While mental illnesses, including depression, have a known association with
cigarette smoking, the general adult population living with HIV also experience a higher
smoking prevalence compared to the general adult population in the United States
(Browning, Wewers, Ferketich, & Diaz, 2013; Centers for Disease Control and
Prevention (CDC),"BRFSS,” 2013). Studies have reported smoking prevalence in the
range of 40-70% among persons living with HIV, compared to the general population
smoking prevalence of 21.4% (Centers for Disease Control and Prevention (CDC), 2013).
In 2013, the Behavioral Risk Factor Surveillance System (BRFSS) estimated only 17.8%
of adults are current smokers, a decrease from the previous estimate of 21.4% (Centers
for Disease Control and Prevention (CDC),"BRFSS,” 2013). Mdodo et al, 2015
examined smoking prevalence and quit ratios among HIV adults in care who participated
in the Medical Monitoring Project compared to adults who participated in the National
Health Interview Survey in 2009 (2015). Smoking prevalence among adults was 42.4%
(95% CI, 39.7% to 45.1%) compared to 20.6% of adults in the general population
(Mdodo et al., 2015). Adults living with HIV were nearly twice as likely to smoke, and
less likely to quit smoking (quit ratio, 32.4% vs. 51.7%) (Mdodo et al., 2015). Adults
living with HIV are disproportionately affected by cigarette smoking compared to the
general adult population.
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Depression may be a factor in the high cigarette smoking prevalence observed in
people living with HIV (Browning et al., 2013). Due to the high proportion of depression
among HIV-positive individuals, smoking may in fact help to mitigate the effects of
depression, as seen in the general adult population (Burkhalter, Springer, Chhabra,
Ostroff, & Rapkin, 2005). HIV-positive individuals that currently smoke also have lower
quit rates compared to the general adult population, and a high prevalence of depression
may impact quit attempts (Burkhalter et al., 2005).
Shuter, Bernstein, and Moadel examined smoking behaviors and beliefs among
persons living with HIV (2012). These individuals were receiving care, and most of the
individuals explained that cigarette smoking helped them cope with anger, depression, or
anxiety (Shuter et al., 2012). Among these participants, 73.3% stated they were currently
depressed or experienced depression in the past (Shuter et al., 2012).
The increased burden of cigarette smoking among persons living with HIV
Cigarette smoking increases risk for diseases for HIV-positive smokers, including
cardiovascular disease, pneumonia, lung cancer, and liver cancer (Helleberg et al., 2013).
HIV-positive smokers are more susceptible to develop chronic obstructive pulmonary
disorder (COPD) compared to smokers in the general population (Crothers et al., 2006).
One study revealed liver cancer risk is synergistically increased by HIV infection and
current tobacco use (Helleberg et al., 2013). The authors also reported a substantial
increase in mortality among HIV-positive smokers compared to HIV-infected nonsmokers (Helleberg et al., 2013). In another study, Helleberg, et al, examined associations
between smoking and mortality among individuals in care with more than one year after
initiation on antiretroviral therapy (ART), excluding injection drug users (Helleberg et
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al., 2015). The mortality rate ratio (MRR) which compared HIV-infected smokers with
HIV-infected nonsmokers was 1.94 (95% CI 1.56-2.41). HIV-positive smokers also
experienced a higher mortality from cardiovascular disease [MRR 6.28 (95% CI 2.1918.0)] (Helleberg et al., 2015). The loss life-years associated with smoking was 7.9 (95%
CI 7.1-8.7) (Helleberg et al., 2015).
2.5 Depression and Substance Use among Adults living with HIV
Previous research has demonstrated a relationship between depression and
substance use in persons living with HIV. Studies have estimated between 10% and 28%
of persons living with HIV have co-occurring substance use disorders and mental illness
disorders, including depression (Burnam et al., 2001; Dausey & Desai, 2003). A national
study that utilized a probability sample of HIV-positive individuals in care revealed that
drug dependence was independently associated with a number of factors, including
screening positive for a psychiatric disorder, including depression (Bing et al., 2001).
Berger-Greenstein et al. estimated a 72% prevalence of depression among HIV-positive
substance users in a low-income, urban setting (2007). Depression and substance use
disorders are also related to low medication adherence, essentially creating a complicated
mechanism of disease progression (Magidson et al., 2014).
Researchers have also found that depressive symptoms are associated with an
increase in risky behaviors, which have an even larger impact on HIV-positive substance
users, particularly injection-drug users (Johnson, Rabkin, Lipsitz, Williams, & Remien,
1999). Depressive symptoms have been related to an increase in needle-sharing, which
increases both the risk of transmissibility of HIV as well as a new infection of a different
strain of HIV to those already infected (Johnson et al., 1999; Berger-Greenstein et al.,
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2007). Persons who are infected with more than one strain of HIV have an increased
probability of experiencing resistance to antiretroviral medications (Berger-Greenstein et
al., 2007).
Although the relationship between depression and substance use has been
explored among persons living with HIV, few articles examine the relationship between
depression and use of specific drugs, especially non-injection drugs, among persons
living with HIV in care. A study which examined co-occurring substance use disorders
with psychological distress found the strongest relationship among opioid users
(McCabe, Feaster, & Mitrani, 2014). Opioid users had three times the odds of having cooccurring psychological distress (OR=2.75, p=0.035) (McCabe et al., 2014). This article
also assessed relationships between psychological distress and use of other substances,
including cannabis, alcohol, and sedatives; however, these relationships were not
statistically significant (McCabe et al., 2014).
2.6 Depression and HIV Medication Adherence
Depression has been linked to a decrease in HIV medication adherence in more
than 95 studies (Gonzalez, Batchelder, Psaros, & Safren, 2011). This meta-analytic
review found that across 95 independent samples depression was significantly (P<0.01)
related to medication non-adherence (r=0.19; 95% CI 0.14-0.25) (Gonzalez et al., 2011).
However, contradicting results were found in a study assessing medication adherence
among HIV-positive substance users with a mental illness, including those with
depression (Berger-Greenstein et al., 2007). The participants were actively receiving care
for HIV, and 72.9% of participants had major depression disorder (Berger-Greenstein et
al., 2007). The researchers found that participants who reported a high number of
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depression symptoms were also likely to report a high rate of medication adherence
compared to individuals reporting a smaller number of depression symptoms (BergerGreenstein et al., 2007). The authors reasoned that depressed individuals are more likely
to be concerned with longevity of life and their health, and they are more likely to take
their medications. They also proposed that medication adherence could have been falsely
reported by these individuals, possibly due to their depression interfering with memory
recall or social desirability bias (Berger-Greenstein et al., 2007).
Although many studies have assessed the relationship of depression to HIV
medication adherence, articles have revealed inconsistent results. Few articles also
explore the relationship between depression and medication adherence among individuals
receiving continuous care for HIV (Berger-Greenstein et al., 2007). Other researchers
have sought to examine the relationships between depression, non-medication adherence,
and other variables.
Medication adherence is measured in a variety of ways. Although medication
adherence is measured primarily by self-reported questionnaires or interviews,
medication adherence can also be measured by viral load (Bonner, Mezochow, Roberts,
Ford, & Cohn, 2013). Most HIV-positive individuals who are adhering to antiretroviral
medications are virally suppressed.
2.7 Summary of Literature Review and Gaps
Individuals living with HIV and co-morbid depression experience more adverse
health behaviors, such as medication non-adherence, current cigarette smoking, and
substance use, compared to individuals living without depression. Untreated depression
negatively affects multi-dimensional aspects of life for persons living with HIV.
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Abstaining from substance use and cigarette smoking behaviors has been shown to
prolong life for this population. Furthermore, adhering to ART medication promotes
healthier, longer lives while substantially decreasing the risk of HIV transmission.
However, these important behaviors are negatively impacted by depression. Since
depression has such a high prevalence in this population compared with the general
population, identifying and treating depression has enormous implications for persons
living with HIV.
Although a substantial amount of literature exists around depression among
persons living with HIV, few studies have consistently evaluated individuals living with
HIV who are currently receiving medical care. By analyzing Medical Monitoring Project
participants in Georgia, this study can provide a unique perspective of the association of
depression on certain health behaviors among individuals currently receiving medical
care for HIV. Most studies reviewed have examined the relationship between depression
and adverse health outcomes; however, no studies to date have assessed the relationship
between depression and adverse health outcomes among HIV-positive adults in Georgia
receiving care. The results will inform public health professionals and healthcare
providers on the importance of screening and treatment of depression among this
population.
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Abstract
Introduction:
Currently there are approximately 1.2 million people in the United States living with HIV
and it is estimated that 25.6% of HIV-positive adults suffer from depression. The purpose
of this study is to examine the contribution of depression on substance use and
medication adherence among HIV-positive adults receiving medical care for HIV.
Methods:
Secondary data with a probability sample of 608 HIV-positive adults who took part in the
2009-2012 Georgia Medical Monitoring Project (MMP) were analyzed. Descriptive
analysis and multivariate logistic regression models were conducted to assess
relationships between depression with current cigarette smoking, injection drug use, other
non-injection drug use, and medication adherence, adjusting for sociodemographic
covariates (age, gender, race, and education). All analyses accounted for non-response
and complex sampling design.
Results:
Among HIV-positive adults in Georgia, approximately 9.2% met the criteria for major
depression; 15.2% of women and 6.9% of men had major depression. Heterosexual adults
also had a higher percentage of major depression (11.9%) compared to adults who
identified as bisexual (8.3%) or homosexual (6.1%). Major depression was also highest
among young adults (17.1%) and adults with high school diploma or GED (13.0%).
Major depression was associated with a greater odds of current cigarette smoking (3.04;
95% CI: 1.48, 6.23); injection drug use (5.62; 95% CI: 0.96, 32.81), and other noninjection drug use (2.17; 95% CI: 1.10, 4.25), after adjusting for sociodemographic
variables. Major depression was also associated with a greater odds of ART medication
non-adherence, 2.52 (95% CI: 1.20, 5.28).
Conclusion:
As previously found in the general population, we found significant associations between
depression and smoking and other non-injection drug use among HIV-positive adults.
Because HIV-positive adults have ongoing encounters with healthcare providers,
screening and treatment for depression and other co-morbid substance use is needed to
reduce an additional health burden in this population.
Key Words: Depression, substance use, cigarette smoking, antiretroviral medication
adherence, HIV, Behavior
Abstract Word Count: 299
Main Text Word Count: 2,975
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Introduction
Approximately 1.2 million people within the United States are currently living
with Human Immunodeficiency Virus (HIV) (“CDC - HIV/AIDS”). According to the
Georgia Department of Public Health HIV/AIDS Epidemiology Section, approximately
50, 436 people were living with HIV in Georgia as of December 31, 2012 (The Georgia
Department of Public Health Fact Sheet: HIV Surveillance, Georgia, 2012). Georgia has
the sixth highest HIV prevalence among adults and adolescents in the United States, and
Georgia ranked fourth highest in the United States for new HIV infections in 2011 (The
Georgia Department of Public Health Fact Sheet: HIV Surveillance, Georgia, 2012).
While individuals living with HIV are living longer lives compared to the era
before antiretroviral therapy (ART), complications and barriers still exist linking and
retaining individuals with HIV to treatment and care. Specific comorbidities are common
to people living with HIV. Mental illness, specifically depression, disproportionately
affects this population, and depression is strongly suspected to be one barrier to accessing
and remaining in care. Among HIV-infected individuals, depression is the most common
neuropsychiatric disorder that affects these individuals (Nanni, Caruso, Mitchell,
Meggiolaro, & Grassi, 2015). Compared to the general population, HIV positive persons
are between two and seven times more likely to be diagnosed with major depression
(Hinkin, Castellon, Atkinson, & Goodkin, 2001; Do et al., 2014).
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Depression among people living with HIV is known to have an effect on several
health outcomes and health behaviors, including medication adherence (Arseniou,
Arvaniti, & Samakouri, 2014). Depression has been linked to a decrease in HIV
medication adherence in more than 95 studies (Gonzalez, Batchelder, Psaros, & Safren,
2011). However, Berger-Greenstein et al found that participants who reported a high
number of depression symptoms were also likely to report a high rate of medication
adherence compared to individuals reporting a smaller number of depression symptoms
(2007).
Other adverse health behaviors, including cigarette smoking and substance use,
have also been associated with depression (McClave, McKnight-Eily, Davis, & Dube,
2010; Strine et al., 2012; Trosclair & Dube, 2010). For example, among persons with any
mental illness, 36.1% are current smokers, substantially higher than the general
population (CDC, 2013). The psychoactive properties of nicotine in tobacco, may be
used to ease symptoms of mental illness, including major depression (McClave et al.,
2010; Strine et al., 2012; Trosclair & Dube, 2010). Due to the high proportion of
depression among HIV-positive individuals, the nicotine from smoking cigarettes may in
fact help to mitigate the effects of depression, as seen in the general adult population
(Burkhalter, Springer, Chhabra, Ostroff, & Rapkin, 2005). Adults living with HIV are
nearly twice as likely to smoke, and less likely to quit smoking (quit ratio, 32.4% vs.
51.7%) (Mdodo et al., 2015). Substance use also has demonstrated an association with
depression, among both the general population and those with HIV. Studies have
estimated between 10% and 28% of persons living with HIV have co-occurring substance
use disorders and mental illness disorders, including depression (Burnam et al., 2001;
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Dausey & Desai, 2003). Depression and substance use disorders are also related to low
medication adherence, essentially creating a complicated mechanism of disease
progression (Magidson et al., 2014).
The purpose of this study is to examine the excess burden of depression on
current cigarette use, injection drug use, non-injection drug use, and ART medication
adherence, among adult Georgians receiving medical care for HIV infection using the
Georgia Medical Monitoring Project Data, 2009-2012. By analyzing depression’s
association with these health behaviors, individuals involved in care of HIV-positive
persons can determine the importance of screening and treating depression.
Methods
Sample and Data Source
The Georgia Medical Monitoring Project (MMP) is a surveillance system that
collects data on behavioral and clinical aspects of persons living with HIV who are
currently receiving medical care (“Georgia Medical Monitoring Project (MMP) | Georgia
Department of Public Health”). For the purposes of the present study, a secondary
analysis was conducted using 2009, 2010, 2011, and 2012 aggregate MMP data.
Institutional Review Board at Georgia State University determined the study to be
exempt.
MMP consists of a three-stage, probability sampling method, and Georgia is one
of 26 states and cities across the United States to participate (“Georgia Medical
Monitoring Project (MMP) | Georgia Department of Public Health”). MMP project areas
are estimated to include over 80% of the total HIV/AIDS patients in the United States.
Interviews are conducted either face-to-face or via phone to ascertain behavioral
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information, and medical record abstractions are used to obtain clinical information. To
be eligible to participate, individuals were required to be HIV-positive, 18 years of age or
older at the time of the interview, and actively receiving medical care for HIV. Data from
the Georgia MMP are weighted to produce a representative sample of all adult Georgians
receiving medical care for HIV (McNaghten et al., 2007; Blair et al., 2011; Frankel et al.,
2012). Once facilities are selected and agree to participate, patient lists are generated and
a random sample of 400 Georgia patients are randomly selected. Patient and facility
response rates are combined into one response rate to report for each year of MMP. For
2009, the combined response rate was 27.39%, the combined response rate for 2010 was
17.58%, the combined response rate for 2011 was 23.23%, and the combined response
rate for 2012 was 34.71%.
Measures
Independent Variables
Depression is measured in MMP using the Eight-Item Patient Health
Questionnaire (PHQ-8) (Kurt Kroenke et al., 2009; K. Kroenke, Spitzer, & Williams,
2001). The PHQ-8 was adopted from the PHQ-9, which assesses the nine criteria
associated with depression as defined by the Diagnostic and Statistical Manual of Mental
Disorders, fourth edition (DSM-IV) (American Psychiatric Association, 2000). The ninth
item that was omitted from the PHQ-8 assesses suicidal ideations, and due to the majority
of interviewers not being trained mental health providers, this item was removed to create
a more widely used tool, the PHQ-8 (Kurt Kroenke et al., 2009; K. Kroenke et al., 2001).
The PHQ-8 has demonstrated to be closely comparable to the PHQ-9 (Kurt Kroenke,
Spitzer, Williams, & Löwe, 2010). According to a systematic review of the PHQ-9, the
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measure has demonstrated internal reliability or 0.86 to 0.89 and external reliability of
0.84 in identifying depression in both clinical settings and general population settings
(Kurt Kroenke et al., 2010).
Methods used to identify individuals with major depression are consistent with
the DSM-IV criteria (American Psychiatric Association, 2000) as well as methods used
to identify major depression in a national MMP study (Do et al., 2014). The PHQ-8 asks
if the individuals experienced certain symptoms within the last two weeks. Individuals
were considered to have major depression if the individual had five out of the eight
symptoms “more than half the days” out of the last two weeks, and the individual
answered “more than half the days” in response to at least one of the first two questions:
1) “Little pleasure in doing things”, 2) “Feeling down, depressed, or hopeless” (Kurt
Kroenke et al., 2009; Do et al., 2014).
Dependent Variables
Injection drug use
Participants who responded that they had used injection drugs in the past 12
months were defined injection drug use. The interviewer explains that injection drugs for
non-medical purposes include using drugs with a needle, “either by mainlining, skin
popping, or muscling.” The participant can identify which drug (heroin, cocaine, heroin
and cocaine together, crack, methamphetamine, amphetamines, oxycontin, steroids or
hormones, or any other drug) and how often the individual used the drug.
Other non-injection drug use
Participants who responded that they had used other non-injection drugs in the
past month (methamphetamines, amphetamines or stimulants, crack, cocaine, downers
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such as Valium, Ativan, Xanax, painkillers such as Oxycontin, Vicodin, Percocet,
hallucinogens such as LSD, or mushrooms, and other drugs like ecstasy, heroin or opium,
marijuana, amyl nitrate, GHB, or ketamine) and how often they used the drug during the
past 12 months (daily, weekly, monthly, less than monthly, never, refused, or don’t
know).
Current Cigarette Smoking
For the descriptive analysis, current cigarette smoking was categorized as current
cigarette smoker, former cigarette smoker, and never smoker. Cigarette smoking was
assessed using the CDC criteria used to assess current smoker status (“CDC Disability
and Health Data System (DHDS)”). Individuals were defined as current smokers if the
individual answered “Yes” to “Have you smoked at least 100 cigarettes in your entire
life?” and if the individual answers “Daily,” “Weekly,” or “Monthly” in response to
“How often do you smoke cigarettes now?” (“CDC Disability and Health Data System
(DHDS)”). To meet the criteria of a former cigarette smoker, participants answered
“Yes” to “Have you smoked at least 100 cigarettes in your entire life?” and “Never” to
“How often do you smoke cigarettes now?” Never smokers were classified if participants
answered “No” to “Have you smoked at least 100 cigarettes in your entire life?”
Individuals were classified as current smokers or non-smokers for the purpose of
the logistic regression analysis. Current smokers were classified using the same
methodology as the descriptive analysis, and former smokers were categorized with never
smokers into the non-smoker category.
ART Medication Adherence
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ART medication adherence was assessed using several questions. Adults who
reported ever taking any antiretroviral medicines were included in the analysis.
Participants who responded they were not currently taking antiretroviral medicines due to
reasons other than doctor advisement, but had taken antiretroviral medicines in the past,
were classified as non-adherent. If participants reported their antiretroviral medicines
consisted of special instructions, such as taking medication with food or with plenty of
fluids, and they reported following those instructions “Never,” “Rarely,” or “About half
of the time,” they were classified as non-adherent. Participants who reported “Most of the
time” or “Always” regarding following their instructions were classified as adherent.
Also, if participants reported “Never,” “Rarely,” or “About half of the time,” to specific
scheduling instructions for ART medications in the past 3 days, they were classified as
non-adherent. Participants were classified as adherent if they reported following their
scheduling instructions “Most of the time” or “Always.” Furthermore, if individuals
reported missing their ART medications in the past week, 1-2 weeks ago, or 3-4 weeks
ago, the participants were classified as non-adherent. If the participant reported the last
time they missed their ART medication as 1-3 months ago, more than 3 months ago, or
reported never skipping medications, they remained classified as adherent.
Drug holidays were also taken into consideration in assessing for medication
adherence. Participants who responded “Yes” to the question, “Have you ever
purposefully taken a ‘drug holiday’ from your antiretroviral medicines that wasn’t
recommended by your doctor?” were classified as non-adherent, whereas participants
who responded “No” were classified as adherent.
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Participants were excluded from the medication adherence analysis if they were
never prescribed antiretroviral medicines due to their doctor’s recommendations or if
they had never taken antiretroviral medicines. Participants were also excluded from the
analysis if they reported having taken ART medicines in the past, were not currently
taking ART medicines, but reported participating in an HIV clinical trial. Individuals who
refused to answer or did not know if they were taking antiretroviral medicines were also
excluded.
Statistical Analyses
All statistical analyses were conducted using SAS 9.2 (SAS Institute, Inc., Cary,
NC). Demographic variables between individuals with major depression and individuals
without major depression were ascertained. All analyses accounted for the complex
survey design and included weights, cluster and stratum variables. Multivariate logistic
regression was conducted to assess associations between depression and dependent
variables using procedures which accounted for complex sampling design. Logistic
regression took into account various confounders based upon bivariate analyses of
confounders in this dataset and previously documented confounders in the literature.
Results
Demographic characteristics (Table 1) displayed differences among adults with
major depression and those without major depression. The overall total weighted
percentage of adults with major depression, 9.2% (95% CI: 6.8%, 11.7%), were similar to
findings in a national MMP study, which found 12.4% (95% CI: 11.2%, 13.7%) of adults
had major depression (Do et al., 2014). A greater percentage of females, 15.2%, were
classified as having major depression (95% CI: 8.8%, 21.6%) compared to 6.9% of males
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(95% CI: 4.6%, 9.1%). An estimated 11.9% (95% CI: 7.8%, 16.1%) of heterosexuals
classified as having major depression, a higher percentage than those who identified as
bisexual, 8.3% (95% CI: 2.2%, 14.4%), or homosexual, gay, or lesbian, 6.1% (95% CI:
3.0%, 9.2%). A higher proportion of individuals whose highest education achieved was a
high school education or GED met the criteria for major depression, 13.0% (95% CI:
8.2%, 17.8%), compared to individuals with a higher level of education.
Adults who reported non-adherence to ART medication had a higher percentage
of major depression, 20.8% (95% CI: 8.8%, 32.8%) compared to adults who reported
adherence to ART medication, 8.2% (95% CI: 5.8%, 10.6%). Among all participants,
9.7% (95% CI: 7.1%, 12.3%) met the criteria for non-adherence to ART medication.
Among those who reported not currently taking antiretroviral medicines, reported reasons
for non-adherence included due to doctor advisement or delay, 24.7% (95% CI: 10.1%,
39.2%), due to side effects, 22.4% (95% CI: 9.4%, 35.4%), worried about ability to
adhere, 7.4% (95% CI: 3.8%, 11.0%), or due to money or insurance issues, 26.4% (95%
CI: 11.9%, 40.8%). As previously mentioned, participants who reported non-adherence
due to doctor advisement to delay or stop treatment were excluded from the analysis.
Logistic regression analyses (Table 2) examined the associations between ART
medication adherence and major depression. After adjusting for gender, major depression
was associated with a higher odds of non-adherence to medication, 2.52 (1.20, 5.28),
compared to adults without major depression.
A higher percentage of current cigarette smokers had major depression, 16.1%
(95% CI: 11.1%, 21.0%), compared to former cigarette smokers, 4.4% (95% CI: 0.5%,
8.4%), and non-smokers, 5.9% (95% CI: 2.7%, 9.2%). Multivariate logistic regression
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analyses compared current smokers to non-smokers. After adjusting for age, gender, race,
and education, the odds of current cigarette smoking among individuals with major
depression was 3.04 (95% CI: 1.48, 6.23) times the odds of current cigarette smoking
among individuals without major depression.
Injection drug users had a much higher percentage of adults with major
depression, 28.2% (95% CI: 2.4%, 54.0%) compared to non-injection drug users, 9.0%
(95% CI: 6.5%-11.5%). However, due to the small sample size of unweighted individuals
with major depression, the confidence interval is unstable. The adjusted odds ratio for
persons with major depression and the association of injection drug use was 5.62 (95%
CI: 0.96, 32.81). Both the injection drug odds ratio and the non-injection drug odds ratio
were adjusted for age, gender, race, and education. Non-injection drug users also had a
similar distribution of individuals with major depression as injection drug users. Among
non-injection drug users, 14.2% (95% CI: 8.3%, 20.1%) had major depression compared
to 7.7% (95% CI: 5.0%, 10.5%) of those who did not use non-injection drugs who had
major depression. The adjusted odds ratio for non-injection drug use and major
depression was 2.17 (95% CI: 1.10, 4.25).
Discussion
Adults with major depression were more likely to report current cigarette
smoking, non-injection drug use in the past 12 months, and ART medication nonadherence compared with individuals without major depression. Even after adjusting for
potential confounders, these relationships were significant. Although injection drug users
had a wide confidence interval and was not statistically significant, a larger raw sample
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size would likely yield a significant relationship between major depression and injection
drug use.
The association of depression and medication non-adherence is one that has been
found in numerous studies, including a recent meta-analysis of 95 studies which showed
a positive relationship between depression and medication non-adherence (Gonzalez,
Batchelder, Psaros, & Safren, 2011). While we examined non-adherence through a
multitude of self-reported measures, the association of depression and medication
adherence could also be explored using viral load. Although the literature has
demonstrated self-reported medication adherence and viral load are both consistent at
operationalizing medication adherence, viral load suppression would be able to reveal
who is virally suppressed and therefore medication adherent. Also, viral load levels could
be longitudinally studied comparing adults with and without depression to examine if a
difference exists with regards to change in viral loads over time, which would also reveal
which adults remain in care. Furthermore, in this questionnaire, adults could report
reasons why they are not currently taking antiretroviral medicines or why they haven’t
ever taken antiretroviral medicines. While “feeling down or depressed” was an option as
a reason for non-adherence, this was not selected by any participants.
The associations with injection and non-injection drugs are commonly found in
the literature among the general population, as well as in adults living with HIV. Selfreported drug use is likely under reported, and the prevalence of injection and noninjection drug use is likely higher. Adults who are not in care may have an even higher
prevalence of injection and non-injection drug use.
Limitations
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Several limitations should be noted in our study. Due to the small sample of
transgender persons, this gender category was excluded from logistic regression analyses
(unweighted n=4, weighted n=159). Future studies should include larger sample sizes of
transgender persons when examining the relationship between depression and behaviors,
especially as this is a group that experiences health disparities, even among HIV-positive
persons.
All measures examined were self-reported, which introduces the possibility of
recall bias and potentially social desirability bias, especially with assessing previous drug
use. As previously mentioned, injection drug users composed a small sample size
(unweighted n= 8, weighted n=274). This is likely an underestimate of the true parameter
of injection drug use. Future studies that include larger samples of HIV-positive persons
would likely solve this issue. Also, obtaining medical histories or medical chart
abstractions regarding previous injection drug use within the past 12 months could also
be a more accurate estimate of injection drug use, as opposed to the self-reported
measure.
Medication adherence analyses excluded individuals who had never taken
antiretroviral medicines and individuals whose doctors delayed antiretroviral treatment
due to CDC guidelines and recommendations for antiretroviral medicines prior to 2012.
Since the guidelines post 2012 include recommending all persons living with HIV to be
prescribed antiretroviral medicines, the effects of this policy may take a few years to be
evident. Evaluating the association between medication adherence and major depression
after this guideline change would be of interest.
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The MMP questionnaire does not assess whether or not the individual is taking
medication for depression. By knowing whether or not an individual is taking
antidepressants, analyses could be conducted on those with untreated depression. Persons
with untreated depression experience more adverse health outcomes than those with
treated depression. Associations of treated depression and medication adherence could be
examined to evaluate if a difference exists compared to associations of untreated
depression and medication adherence in this population of Georgians to evaluate if these
associations are consistent with the literature.
Lastly, the burden of depression among HIV-positive adults currently receiving
care may underestimate the overall burden of depression among HIV-positive adults.
Those seeking medical care may be more health-conscious. These individuals may also
have less adverse health behaviors than the general HIV-positive population in the United
States.
Implications and Recommendations
The associations of depression with these health behaviors have enormous
implications for depression treatment and screening for HIV-positive persons. Guidelines
do exist for HIV specific care providers that take into account screening and treatment of
depression (Aberg et al., 2009). Screening for depression has not been consistently
implemented in HIV care provider settings, although recommended as part of HIV
medical care guidelines (Shacham et al., 2009). Shacham et al demonstrated the PHQ-9
as a feasible screening tool for HIV care providers (2009).
Smoking cessation programs for individuals with HIV should also address
potential depression. Tobacco use and cigarette smoking has additional implications for
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HIV-positive individuals, including increasing risks for cardiovascular disease,
pneumonia, lung cancer, and liver cancer (Helleberg et al., 2013). Studies have
demonstrated a substantial increase in mortality among smokers living with HIV, more
than smoking or HIV alone (Helleberg et al., 2013). HIV providers and infectious disease
providers need to recognize the importance of tobacco cessation within this population.
Shuter, Bernstein, et al. examined smoking behaviors among people living with HIV, and
83% of participants revealed their primary care provider discussed smoking cessation
with them (2012). However, only 32.8% were referred to a quit line and 5.3% were
referred to a smoking cessation program (Shuter et al., 2012).
A recent review assessed tobacco cessation programs among HIV-positive
persons (Moscou-Jackson, Commodore-Mensah, Farley, & DiGiacomo, 2014).
Interventions which incorporated cell phone cessation strategies were the most successful
at smoking cessation rates (Vidrine, Arduino, Lazev, & Gritz, 2006; Vidrine, Marks,
Arduino, & Gritz, 2012). The review concluded that the most successful interventions
were adjusted to address specific needs of people living with HIV (Moscou-Jackson et
al., 2014). Also, interventions that addressed co-occurring substance use and psychiatric
disorders were also more successful at achieving tobacco cessation than interventions that
did not address these comorbidities (Moscou-Jackson et al., 2014).
Future studies should also aim at assessing substance use and smoking cessation
interventions that incorporate depression screening and treatment. Depression could be
the underlying factor impeding successful treatment of co-occurring substance use and
tobacco use. The treatment of depression could increase the overall well-being of persons
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living with HIV, as well as having an effect on the reduction of substance or cigarette
smoking behaviors.
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Table 1. Demographic characteristics among adults with major depression and without major depression

Major Depression
N*

Weighted
N

Gender
Male

29

977

Female

22

893

Transgender**
Sexual Orientation
Homosexual, gay, or lesbian

0

---

14

483

Bisexual

6

188

Heterosexual

29

1,150

Other**
Race/Ethnicity
Alaskan Native/American Indian**
Asian**
Black/African American

2

50

0
0
28

----1,054

White/Caucasian

16

589

Multi-Racial

6

190

Hispanic/Latino**
Age
18-24**

1

Without Major Depression

Percentage
(95% CI)

N

Weighted
N

6.88%
(4.63%-9.12%)
15.21%
(8.78%-21.64%)
---

392

13,224

144

4,977

4

159

6.11%
(3.03%-9.18%)
8.30%
(2.16%-14.43%)
11.94%
(7.76%-16.11%)
---

220

7,421

60

2,076

252

8,483

5

276

2
2
365

77
78
12,346

121

3,967

45

1,674

36

----7.87%
(4.56%-11.17%)
12.93%
(8.13%-17.73%)
10.20%
(2.40%-18.00%)
---

4

177

6

233

---

30

1,137

25-34**

9

271

---

70

2,374

35-44**

7

305

---

162

5,675

45-54

23

872

174

5,892

> 55**

6

187

12.90%
(8.01%-17.79%)
---

102

3,189

Education
High School/GED

30

1,148

225

7,656

Some college

15

524

13.04%
(8.24%-17.85%)
7.05%

200

6,907

Total MMP Participants

Percentage
(95% CI)

N

Weighted
N

93.12%
(90.88%-95.37%)
84.79%
(78.36%-91.22%)
---

421

14,201

166

5,870

4

159

93.89%
(90.82%-96.97%)
91.70%
(85.57%-97.84%)
88.06%
(83.89%-92.24%)
---

234

7,903

66

2,264

281

9,633

7

326

----92.13%
(88.83%-95.44%)
87.07%
(82.27%-91.87%)
89.80%
(82.00%-97.60%)
---

2
2
393

77
78
13,400

137

4,556

51

1,864

5

213

82.95%
(70.67%-95.24%)
89.76%
(81.73%-97.80%)
94.89%
(90.52%-99.26%)
87.10%
(82.21%-91.99%)
94.46%
(90.11%-98.80%)

36

1,371

79

2,645

169

5,980

197

6,764

108

3,376

86.96%
(82.15%-91.76%)
92.95%

255

8,804

215

7,431

Percentage
(95% CI*
70.20%
(64.46%-75.93%)
29.02%
(23.58%-34.46%)
--39.27%
(31.28%-47.26%)
11.25%
(8.96%-13.54%)
47.86%
(41.58%-54.14%)
------66.37%
(61.81%-70.93%)
22.57%
(17.82%-27.31%)
9.24%
(6.33%-12.13%)
--6.78%
(4.68%-8.87%)
13.07%
(10.34%-15.81%)
29.56%
(25.91%-33.22%)
33.44%
(30.17%-36.70%)
16.69%
(14.02%-19.36%)
43.52%
(36.33%-50.71%)
36.73%
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Bachelor’s Degree**

4

142

(3.31%-10.79%)
---

77

2,566

Post-graduate studies**

2

56

---

38

1,230

Total

51

1,870

9.24%
(6.78%-11.70%)

540

18,360

(89.21%-96.69%)
94.76%
(89.92%-99.60%)
95.67%
(89.51%-100%)
90.76%
(88.30%-93.22%)

81

2,708

40

1,286

591

20,230

*Unweighted N totals may not add up consistently due to missing variables. Missing variables were not reported if they comprised less than 10% of the total sample size.
**Weighted percentages were suppressed if estimates had a coefficient of variance >30%.
***Column percentages reported for total MMP participant column, whereas row percentages are reported for characteristics comparing major depression and no major depression.

(32.35%-41.12%)
13.39%
(9.30%-17.47%)
6.36%
(3.72%-8.99%)
100%
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Table 2. Associations of major depression with dependent variables
Row percent

Unadjusted
OR**

PValue

Adjusted
OR***

PValue

8.45% (6.0, 10.9)
21.3% (9.6, 33.1)

1.00 Referent
3.01 (1.26, 7.18)

0.01*

1.00 Referent
2.52 (1.20, 5.28)

0.01*

32.3% (27.6, 37.0)
62.4% (46.3, 78.4)

1.00 Referent
3.48 (1.75, 6.91)

0.0004*

1.00 Referent
3.04 (1.48, 6.23)

0.003*

22.3% (18.0, 26.5)
36..1% (21.8, 50.5)

1.00 Referent
1.98 (1.06, 3.70)

0.03*

1.00 Referent
2.17 (1.10, 4.25)

0.03*

-----

1.00 Referent
3.99 (1.06, 14.99)

0.04*

1.00 Referent
5.62 (0.96, 32.81)

0.06

Dependent Variables
Medication Non-Adherence
No Major depression
Major Depression
Current smoker
No Major Depression
Major Depression
Non-injection Drug Use
No Major Depression
Major Depression
Injection Drug Use****
No Major Depression
Major Depression

*Significant values at P<0.05.
**Unadjusted OR obtained from bivariate analyses.
***Adjusted based upon bivariate analyses and the presence of confounders in the literature among noted variables. Medication
adherence was adjusted for gender. Current cigarette smoking, non-injection drug use, and injection drug use were adjusted for age,
gender, race, and education.
****Percentages suppressed if coefficient of variation >30%.
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Table 3.a. Demographics among adults reporting adherence to ART medication and persons reporting non-adherence to ART medication

Adherence to ART medication
N*

Weighted N

Gender
Male

385

12,912

Female

134

4,764

Transgender**
Sexual Orientation
Homosexual, gay, or lesbian

3

119

211

7,103

Bisexual**

55

1,832

Heterosexual

248

8,502

Other**
Race/Ethnicity
American Indian/Alaskan Native**
Asian**
African American

4

203

1
2
344

31
78
11,711

White

124

4,094

Multi-Racial**

44

1,572

Hispanic/Latino**
Age
18-24

5

213

29

1,110

25-34

66

2,218

35-44

142

4,888

45-54

176

6,137

> 55

109

3,442

Education
High School/GED

231

8,019

Some college

186

6,406

Non-adherence to ART
medication

Percentage
(95% CI)

N

Weighted
N

72.56%
(67.29%-77.83%)
26.88%
(21.67%-31.88%)
---

27

889

28

981

1

40

40.26%
(32.75%-47.78%)
10.39%
(7.77%-13.01%)
48.20%
(41.65%-54.74%)
---

16

536

7

254

32

1,097

1

23

----66.16%
(60.65%-71.67%)
23.13%
(18.10%-28.16%)
8.88%
(6.01%-11.75%)
---

0
0
41

----1,381

10

318

5

Total MMP Participants

Percentage
(95% CI)

N

Weighted N

46.55%
(28.69%-64.41%)
51.35%
(33.28%-69.42%)
---

412

13,802

162

5,745

4

159

28.06%
(14.09%-42.03%)
---

227

7,639

62

2,087

57.41%
(43.55%-71.27%)
---

280

9,599

5

226

1
2
385

31
78
13,093

134

4,413

211

----72.30%
(52.55%-92.06%)
16.66%
(7.64%-25.69%)
---

49

1,783

0

---

---

5

213

6.24%
(4.06%-8.41%)
12.47%
(9.59%-15.34%)
27.47%
(24.00%-30.93%)
34.49%
(30.77%-38.20%)
19.34%
(16.08%-22.60%)

4

132

---

33

1,242

8

276

---

74

2,495

17

615

159

5,503

20

640

196

6,777

6

176

32.21%
(19.34%-45.09%)
33.51%
(21.57%-45.45%)
---

115

3,618

45.06%
(35.51%-54.62%)
36.00%

24

835

255

8,854

20

656

43.68%
(30.88%-56.49%)
34.33%

206

7,062

Percentage
(95% CI)
70.04%
(64.46%-75.61%)
29.16%
(23.86%-34.45%)
--39.07%
(31.46%-46.68%)
10.67%
(8.19%-13.16%)
49.10%
(42.86%-55.33%)
------66.76%
(61.97%-71.55%)
22.50%
(17.60%-27.41%)
9.09%
(6.09%-12.09%)
--6.30%
(4.24%-8.37%)
12.66%
(9.80%-15.51%)
27.93%
(24.53%-31.33%)
34.39%
(31.08%-37.71%)
18.36%
(15.44%-21.28%)
44.93%
(36.60%-53.26%)
35.84%

53

Bachelor’s Degree**

72

2,371

Post-graduate studies**

33

999

Major Depression
Yes

38

1,417

No

470

15,840

Total

508

17,258

(29.50%-42.50%)
13.32%
(9.44%-17.20%)
5.62%
(3.60%-7.63%)
8.21%
(5.83%-10.59%)
91.79%
(89.41%-94.17%)
90.33%
(87.75%-92.91%)

8

284

(20.13%-48.53%)
---

80

2,655

4

136

---

37

1,136

11

385

49

1,802

43

1,463

513

18,360

54

1,847

20.82%
(8.84%-32.80%)
79.18%
(67.20%-91.16%)
9.67%
(7.09%-12.25%)

562

19,105

*Unweighted N totals may not add up consistently due to missing variables. Missing variables were not reported if they comprised less than 10% of the total sample size.
**Weighted percentages were suppressed if estimates had a coefficient of variance >30%.
***Column percentages reported

(30.45%-41.22%)
13.47%
(9.47%-17.48%)
5.76%
(3.76%-7.77%)
9.24%
(6.78%-11.70%)
90.76%
(88.30%-93.22%)
100%
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Table 3.b. Demographics among adults who used injection drugs in the past 12 months and persons who did not use injection drugs in the
past 12 months

Injection Drug Use in the Past
12 Months**
N*

Weighted
N

No Injection Drug Use in the
Past 12 Months

Percentage
(95% CI)

N

Weighted N

Gender
Male

7

238

---

424

14,354

Female

1

36

---

172

6,085

Transgender
Sexual Orientation
Homosexual, gay, or lesbian

0

0

---

4

159

6

206

---

231

7,819

Bisexual

1

36

---

66

2,276

Heterosexual

1

32

---

292

10,021

Other
Race/Ethnicity
Alaskan Native/American Indian
Asian
African American

0

---

---

7

325

0
1
0

--49
---

-------

2
1
408

77
29
13,950

White

6

189

---

132

4,404

Multi-Racial

1

36

---

50

1,828

Hispanic/Latino
Age
18-24

0

---

---

5

213

1

49

---

36

1,362

25-34

2

68

---

79

2,665

35-44

2

52

---

169

5,976

45-54

3

105

---

197

6,800

> 55

0

---

---

117

3,701

Education

Total MMP Participants

Percentage
(95% CI)

N

Weighted N

69.69%
(63.89%-75.49%)
29.54%
(24.04%-35.04%)
---

431

14,592

173

6,121

4

159

38.25%
(30.52%-45.98%)
11.14%
(8.75%-13.52%)
49.02%
(42.62%-55.42%)
---

237

8,025

67

2,313

293

10,053

7

325

----68.04%
(63.51%-72.57%)
21.48%
(16.77%-26.20%)
8.92%
(6.19%-11.65%)
---

2
2
408

77
78
13,950

138

4,593

51

1,864

5

213

6.61%
(4.53%-8.70%)
12.94%
(10.47%-15.41%)
29.01%
(25.40%-32.63%)
33.01%
(29.73%-36.30%)
17.97%
(15.18%-20.75%)

37

1,411

81

2,733

171

6,028

200

6,905

117

3,701

Percentage
(95% CI*
69.91%
(64.00%-75.83%)
29.33%
(23.72%-34.92%)
--38.74%
(30.81%-46.67%)
11.16%
(8.81%-13.52%)
48.52%
(42.12%-54.93%)
------67.14%
(62.48%-71.81%)
22.11%
(17.33%-26.89%)
8.97%
(6.17%-11.78%)
--6.76%
(4.71%-8.81%)
13.10%
(10.51%-15.68%)
28.88%
(25.38%-32.38%)
33.08%
(29.78%-36.39%)
17.73%
(14.94%-20.52%)

55

High School/GED

1

32

---

266

9,228

Some college

5

152

---

213

7,401

Bachelor’s Degree

2

90

---

81

2,683

Post-graduate studies

0

---

---

40

1,286

Major Depression
Yes

2

77

---

49

1,792

No

6

197

---

534

18,163

Total

8

274

---

600

20,597

44.80%
(37.26%-52.33%)
35.93%
(31.24%-40.63%)
13.03%
(9.10%-16.95%)
6.24%
(3.62%-8.87%)

267

9,259

218

7,553

83

2,773

40

1,286

8.98%
(6.45%-11.51%)
91.02%
(88.49%-93.55%)
98.69%
(97.65%-99.72%)

51

1,870

540

18,360

608

20,871

*Unweighted N totals may not add up consistently due to missing variables. Missing variables were not reported if they comprised less than 10% of the total sample size.
**Weighted percentages were suppressed if estimates had a coefficient of variance >30%.
***Row percentages reported

44.36%
(36.91%-51.82%)
36.19%
(31.65%-40.73%)
13.29%
(9.23%-17.34%)
6.16%
(3.58%-8.74%)
9.24%
(6.78%-11.70%)
90.76%
(88.30%-93.22%)
100%
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Table 3.c. Demographics among adults who used non-injection drugs in the past 12 months and persons who did not use non-injection
drugs in the past 12 months

Non-Injection Drug Use in the
Past 12 Months
N*

Weighted
N

Gender
Male

111

3,880

Female

25

885

Transgender**
Sexual Orientation
Homosexual, gay, or lesbian

2

46

72

2,462

Bisexual**

14

486

Heterosexual

49

1,711

Other**
Race/Ethnicity
American Indian/Alaskan Native**
Asian**
African American

1

73

0
1
84

0
49
2,995

White

41

1,425

Multi-Racial

11

Hispanic/Latino**
Age
18-24

No Non-Injection Drug Use in
the Past 12 Months

Percentage
(95% CI)

N

Weighted
N

80.66%
(72.83%-88.49%)
18.39%
(10.83%-25.95%)
---

320

10,712

148

5,236

2

113

52.04%
(27.80%-41.81%)
---

165

5,563

53

1,827

36.16%
(24.76%-47.56%)
---

244

8,342

6

252

2
1
324

77
29
10,956

97

3,168

302

----62.77%
(51.90%-73.65%)
29.87%
(18.25%-41.50%)
---

40

1,562

0

---

---

5

213

18

575

19

836

25-34

22

760

59

1,974

35-44

42

1,444

129

4.584

45-54

40

1,546

160

5,360

> 55**

16

486

11.96%
(6.96%-16.97%)
15.79%
(9.13%-22.45%)
30.01%
(20.89%-39.13%)
32.13%
(23.18%-41.08%)
---

101

3,214

Education

Total MMP Participants

Percentage
(95% CI)

N

Weighted N

66.70%
(60.45%-72.94%)
32.60%
(26.70%-38.50%)
---

431

14,592

173

6,121

4

159

32.21%
(27.80%-41.81%)
11.43%
(8.76%-14.10%)
52.19%
(46.23%-58.14%)
---

237

8,025

67

2,313

293

10,053

7

325

----68.45%
(63.96%-72.93%)
19.79%
(15.75%-23.83%)
9.76%
(6.44%-10.09%)
1---

2
2
408

77
78
13,950

138

4,593

51

1,864

5

213

5.20%
(3.10%-7.31%)
12.29%
(9.53%-15.04%)
28.54%
(24.42%-32.67%)
33.37%
(29.54%-37.21%)
20.01%
(17.03%-22.99%)

37

1,411

81

2,733

171

6,028

200

6,905

117

3,701

Percentage
(95% CI)
69.91%
(64.00%-75.83%)
29.33%
(23.72%-34.92%)
--38.74%
(30.81%-46.67%)
11.16%
(8.81%-13.52%)
48.52%
(42.12%-54.93%)
------67.14%
(62.48%-71.81%)
22.11%
(17.33%-26.89%)
8.97%
(6.17%-11.78%)
--6.76%
(4.71%-8.81%)
13.10%
(10.51%-15.68%)
28.88%
(25.38%-32.38%)
33.08%
(29.78%-36.39%)
17.73%
(14.94%-20.52%)
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High School/GED

61

2,066

Some college

52

1,874

Bachelor’s Degree

17

561

Post-graduate studies

8

309

Major Depression
Yes

18

676

No

119

4,086

Total

138

4,811

42.95%
(31.60%-54.31%)
38.96%
(28.39%-49.53%)
11.66%
(5.81%-17.50%)
---

206

7,193

166

5,679

66

2,212

32

977

14.19%
(8.26%-20.12%)
85.81%
(79.88%-91.74%)
23.05%
(18.93%-27.17%)

33

1,194

421

14,273

470

16,601

44.79%
(37.31%-52.26%)
35.36%
(30.13%-40.59%)
13.77%
(9.33%-18.21%)
6.08%
(3.61%-8.55%)

267

9,259

218

7,553

83

2,773

40

1,286

7.72%
(4.98%-10.46%)
92.28%
(89.54%-95.02%
76.95%
(72.83%-81.07%)

51

1,870

540

18,360

608

20,871

*Unweighted N totals may not add up consistently due to missing variables. Missing variables were not reported if they comprised less than 10% of the total sample size.
**Weighted percentages were suppressed if estimates had a coefficient of variance >30%.
***Column percentages reported

44.36%
(36.91%-51.82%)
36.19%
(31.65%-40.73%)
13.29%
(9.23%-17.34%)
6.16%
(3.58%-8.74%)
9.24%
(6.78%-11.70%)
90.76%
(88.30%-93.22%)
100%
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Table 3.d. Demographics among current smokers, former smokers, and never-smokers
Current Smokers
Former Smokers
Never-Smokers
N

Weighted
N

Gender
Male

151

5,082

Female

61

2,344

Transgender**
Sexual Orientation
Homosexual, gay, or
lesbian
Bisexual

2

46

79

2,706

21

643

Heterosexual

113

4,099

Other**
Race/Ethnicity
American Indian/
Alaskan Native**
Asian**
African American

1

Percentage
(95% CI)

N

Weighted
N

68.02%
(58.55%-77.48%)
31.37%
(21.84%-40.90%)
---

87

2,934

39

1,321

0

---

40

1,437

18

600

65

2,069

23

36.21%
(23.89%-45.53%)
8.61%
(4.42%-12.80%)
54.87%
(42.88%-66.85%)
---

1

0

---

---

0
132

--4,652

White

56

1,898

Multi-Racial**

23

796

Hispanic/Latino**

3

Age
18-24**

Percentage
(95% CI)

N

Weighted
N

68.96%
(58.97%-78.95%)
31.04%
(21.05%-41.03%)
---

192

6,551

72

2,405

0

113

118

3,883

27

1,044

114

3,833

73

34.39%
(23.10%-45.68%)
14.36%
(8.36%-20.37%)
49.50%
(39.24%-59.77%)
---

5

1

46

---

1
79

29
2,639

33

1,098

11

126

--62.26%
(55.18%-69.34%)
25.40%
(18.45%-32.35%)
10.65%
(6.07%-15.23%)
---

12

408

25-34**

34

1,298

35-44

63

2,186

45-54

75

2,660

> 55

30

920

Education
High School/GED

123

4,366

Some college

72

2,545

Bachelor’s Degree

14

409

Post-graduate

5

151

Total MMP Participants

Percentage
(95% CI)

N

Weighted
N

Percentage
(95% CI)

72.23%
(65.82%-78.65%)
26.52%
(19.72%-33.32%)
---

430

14,567

70.05%
(64.28%-75.82%)
29.19%
(23.71%-34.67%)
---

172

6,070

4

159

237

8,025

66

2,288

292

10,002

229

43.19%
(36.65%-49.73%)
11.62%
(8.04%-15.19%)
42.64%
(36.44%-48.84%)
---

7

325

38.88%
(31.05%-46.71%)
11.08%
(8.71%-13.45%)
48.46%
(42.18%-54.73%)
---

1

31

---

2

77

---

1
195

48
6,584

78
13,875

49

1,598

138

4,593

17

666

51

1,864

0

---

---

2

87

--73.04%
(67.39%-78.68%)
17.72%
(12.29%-23.16%)
7.38%
(3.06%-11.71%)
---

2
406

403

--62.60%
(52.64%-72.57%)
26.05%
(17.35%-34.75%)
---

5

213

--67.02%
(62.38%-71.67%)
22.19%
(17.44%-26.94%)
9.01%
(6.17%-11.84%)
1.03%
(0.31%-1.75%)

---

3

154

---

22

849

37

1,411

17.37%
(11.74%-23.00%)
29.25%
(22.46%-36.05%)
35.60%
(27.06%-44.14%)
12.31%
(8.62%-16.00%)

1

19

---

46

1,417

81

2,733

29

1,117

79

2,725

171

6,028

44

1,486

79

2,683

198

6,830

48

1,456

26.26%
(18.34%-34.18%)
34.93%
(25.64%-44.23%)
34.23%
(25.59%-42.87%)

39

1,324

9.36%
(5.92%-12.80%)
15.62%
(12.13%-19.11%)
30.04%
(24.29%-35.80%)
29.59%
(23.99%-35.18%)
14.60%
(10.49%-18.72%)

117

3,701

58.44%
(50.00%-66.88%)
34.06%
(27.38%-40.75%)
5.47%
(2.13%-8.81%)
---

50

1,598

94

3,295

9,259

1,722

95

3,211

216

7,477

20

690

49

1,674

83

2,773

7

245

28

890

36.33%
(28.44%-44.21%)
35.41%
(29.09%-41.73%)
18.46%
(13.14%-23.78%)
9.81%

267

49

37.56%
(27.47%-47.66%)
40.46%
(33.45%-47.47%)
16.22%
(8.71%-23.72%)
---

40

1,286

6.79%
(4.73%-8.84%)
13.14%
(10.54%-15.75%)
28.98%
(25.48%-32.50%)
32.84%
(29.50%-36.18%)
17.80%
(15.00%-20.59%)
44.53%
(36.90%-52.15%)
35.96%
(31.27%-40.64%)
13.33%
(9.30%-17.37%)
6.18%

59

studies**
Major Depression
Yes**

(4.90%-14.72%)
29

1,166

16.06%
6
179
--16
524
5.93%
51
(11.13%-20.99%)
(2.66%-9.21%)
No
180
6,094
83.94%
115
3,876
95.58%
243
8,314
94.07%
538
(79.01%-88.87%)
(91.63%-99.52%)
(90.79%-97.34%)
Total
214
7,472
35.93%
126
4,255
20.46%
266
9,069
43.61%
606
(30.74%-41.12%)
(16.92%-24.00%)
(38.27%-48.95%)
*Unweighted N totals may not add up consistently due to missing variables. Missing variables were not reported if they comprised less than 10% of the total sample size.
**Weighted percentages were suppressed if estimates had a coefficient of variance >30%.
***Row percentages reported

(3.61%-8.76%)
1,870
18,284
20,796

9.28%
(6.80%-11.76%)
90.72%
(88.24%-93.20%)
100%
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Table 3.e. Bivariate associations of major depression with demographic variables
Demographic Variables

Gender
Male
Female
Race
White
Black/African American
Other
Education
High School/GED
Post-High School
Age
*Significance at p<0.05

Unadjusted Odds Ratio

P-Value

1.00 Referent
2.09 (1.24, 3.50)

0.006*

1.00 Referent
0.58 (0.30, 1.12)
0.76 (0.27, 2.10)

0.10
0.60

1.00 Referent
0.45 (0.23, 0.87)
0.99 (0.96, 1.02)

0.02*
0.46

